We read with great excitement and interest the article by Friedlaende et al. [1] entitled ‘Impact of performance status on non-small cell lung cancer patients a PD-L1 tumour proportion score ≥...

The goal of radiation therapy for non-small cell lung cancer (NSCLC) is to improve the survival rate of patients without increasing treatment-related toxicity and to improve patients' quality of life. Several prospective randomized trials have demonstrated a survival advantage in combined modality treatment over radiotherapy or chemotherapy alone when a cisplatin-based chemotherapy regimen is u...

Non small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancers. Despite improvements in treatment protocols the survival rate in NSCLC remains poor. An improved understanding of cancer biology has led to the investigation of angiogenesis in NSCLC development and progression by intratumoral microvessel count or expression of angiogenic markers. The prognostic significance ...

Lung cancer is the leading cause of cancer-related mortality worldwide, and more than 80% of cases are of non-small cell lung cancer. Although chemotherapy and molecularly targeted therapy may provide some benefit, there is a need for newer therapies for the treatment of patients with advanced NSCLC. Immunotherapy aims to augment the recognition of cancer as foreign, to stimulate immune respons...

Staging of lung cancer serves 2 purposes; it attempts to classify patients into groups where particular treatments are appropriate and defines those groups based on expected prognosis. The eighth edition of the International Association for the Study of Lung Cancer staging system deals with the issues raised by screening with fine cut computed tomography. Each phase of staging is a legitimate d...